All lobbying filings

S-3 Group

S-3 Group filed a registration for Viatris (Mylan, Inc.) on April 21, 2025.

Lobbying for Viatris (Mylan, Inc.) · Generics and specialty pharmaceutical company

As filed: S-3 GROUP for VIATRIS (MYLAN, INC).

All filings by S-3 Group · Everything Viatris (Mylan, Inc.) has reported

Filing · LD-1 registration Registration

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Pennsylvania

Official filing document

Lobbyists on this filing 5

ASHLEY DAVIS New on this filing

Previously held: Special Assistant to the Homeland Security Director, Executive Office of the President; Deputy Director of Management and Administration, Executive Office of the President
KRISTI REMINGTON New on this filing

Previously held: Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform Committee
SHIMON STEIN New on this filing

Previously held: Senior Policy Advisory, House Majority Leader Eric Cantor, Program Manager, US Department of Justice, Legislative Correspondent, Senator John Ashcroft; Paid Intern, Representative Robert Aderholt
MALLOY MCDANIEL New on this filing

Previously held: Policy Advisor, Senate Minority Leader Mitch McConnell; Whip Liaison, Senate Majority Whip Mitch McConnell; Floor Assistant, Senate Majority Leader Trent Lott; Cloakroom Assistant, Office of the Republican Secretary
CHRISTOPHER BUKI New on this filing

Previously held: Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinley

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Lobbying activity 1

Health Issues

Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing

Bills named in this filing 2

S. 1302
Increasing Transparency in Generic Drug Applications Act
H.R. 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.